Personalized therapeutic strategies in HER2-driven gastric cancer
Sign Up to like & getrecommendations! Published in 2021 at "Gastric Cancer"
DOI: 10.1007/s10120-021-01165-w
Abstract: Trastuzumab is the only approved targeted therapy in patients with HER2-amplified metastatic gastric cancer (GC). Regrettably, in clinical practice, only a fraction of them achieves long-term benefit from trastuzumab-based upfront strategy. To advance precision oncology,… read more here.
Keywords: her2 driven; gastric cancer; trastuzumab; strategies her2 ... See more keywords